Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CAN008 Plus TMZ During and After Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma

NCT05447195 is registered in ClinicalTrials.gov with CANbridge Life Sciences Ltd. as lead sponsor.

NCT NCT05447195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05447195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CAN008 Plus TMZ During and After Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
Lead sponsor
CANbridge Life Sciences Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
October 10, 2021
Completion date
August 31, 2024
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly-diagnosed glioblastoma